Intrinsic Value of S&P & Nasdaq Contact Us

Becton, Dickinson and Company BDXA NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • USD

SharesGrow Score
68/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Becton, Dickinson and Company (BDXA) trades at a trailing P/E of 10.2. Trailing earnings yield is 9.84%.

Criteria proven by this page:

  • VALUE (100/100, Pass) — P/E is below market average (10.2); earnings yield beats bond yields (9.84%).
  • Trailing Earnings Yield 9.84% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.

Overall SharesGrow Score: 66/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
68/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
N/A
No coverage
PAST
100/100
→ Income
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
MOAT
73/100
→ Income
~
GROWTH
40/100
→ Income
~
INCOME
45/100
→ Income

Valuation Snapshot — BDXA

Valuation Multiples
P/E (TTM)10.2
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.78
EV/EBITDA0.0
Per Share Data
EPS (TTM)$5.83
Book Value / Share$0.00
Revenue / Share$76.06
FCF / Share$0.00
Yields & Fair Value
Earnings Yield9.84%
Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $4.49 $12.48B $976M 7.8%
2017 $4.60 $12.09B $1.1B 9.1%
2018 $1.18 $15.98B $311M 1.9%
2019 $3.94 $17.29B $1.22B 7.1%
2020 $2.72 $17.12B $874M 5.1%
2021 $6.85 $20.25B $2.09B 10.3%
2022 $5.88 $18.87B $1.78B 9.4%
2023 $4.94 $19.37B $1.48B 7.7%
2024 $5.86 $20.18B $1.71B 8.4%
2025 $5.83 $21.84B $1.68B 7.7%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message